ライフサイエンスコーパス: triamcinolone acetonide

1 ile, and a slightly long-lasting effect than triamcinolone acetonide.

2 a potentiating effect on the cytotoxicity of triamcinolone acetonide.

3 on of xylocaine alone or in combination with triamcinolone acetonide.

4 bone loss and who were treated with inhaled triamcinolone acetonide (100 microg per puff).

5 ons (9453 ranibizumab, 5386 bevacizumab, 935 triamcinolone acetonide, 121 pegaptanib sodium) were rev

6 viability of ARPE-19 cells after exposure to triamcinolone acetonide (200 microg/mL) alone without th

7 The R28 cells exposed to triamcinolone acetonide (200 microg/mL) without the vehi

8 dophthalmitis per injection was 2 in 935 for triamcinolone acetonide, 3 in 9453 for ranibizumab, and

9 Patients received intravitreal triamcinolone acetonide (32 eyes) or intravitreal bevaci

10 intervention: Patients received intravitreal triamcinolone acetonide (32 eyes) or intravitreal bevaci

11 d with the chaperones in the presence of [3H]triamcinolone acetonide ([3H]TA), which binds to the rec

12 week run-in period of treatment with inhaled triamcinolone acetonide (400 microg twice per day).

13 They used inhaled triamcinolone acetonide, 600 mcg, or placebo, twice dail

14 aser may be more effective than intravitreal triamcinolone acetonide alone.

15 Topical therapy with moderate doses of triamcinolone acetonide, an anti-inflammatory glucocorti

16 ization was improved in 15 patients by using triamcinolone acetonide and in the remaining 15 patients

17 corticosteroids (budesonide, dexamethasone, triamcinolone acetonide, and dexamethasone acetate) rang

18 e Flt23k nanoparticles, blank nanoparticles, triamcinolone acetonide, and PBS groups following subcon

19 (GCs) dexamethasone, mometasone furoate, and triamcinolone acetonide are pharmaceutical mainstays to

20 corticosteroids; intralesional injection of triamcinolone acetonide at the ulcer margin; topical cro

21 The effects of triamcinolone acetonide cream 0.025% were assessed based

22 ant Q642V, which has an altered affinity for triamcinolone acetonide, dexamethasone, and corticostero

23 This study compared computer-modeled triamcinolone acetonide diffusion after posterior sub-Te

24 Treatment with topical triamcinolone acetonide dramatically reduced pathology b

25 hma receiving beclomethasone dipropionate or triamcinolone acetonide during a 2-wk, single-blind, run

26 cts of intra-articular injection of 40 mg of triamcinolone acetonide every 3 months on progression of

27 Four synthetic glucocorticoids (triamcinolone acetonide, fluocinolone acetonide, clobeta

28 Intravitreal triamcinolone acetonide followed by laser may be more ef

29 tained-release suspension releasing 5-FU and triamcinolone acetonide for 1 month.

30 50, 100, and 200 microg/mL concentration of triamcinolone acetonide for 2, 6, and 24 hours.

31 retical model predicts efficient delivery of triamcinolone acetonide from the posterior sub-Tenon's s

32 In the triamcinolone acetonide group, 12 months after surgery t

33 th intravitreal injections of bevacizumab or triamcinolone acetonide in patients with macular edema a

34 In contrast, triamcinolone acetonide-induced luciferase activity was

35 hanges following suprachoroidal injection of triamcinolone acetonide injectable suspension (CLS-TA),

36 Intraoperative intravitreal triamcinolone acetonide injection induces earlier and ma

37 Intravitreal triamcinolone acetonide injection therapy, in particular

38 , 3 days, and 1, 2, 3, 4, and 8 weeks) after triamcinolone acetonide injection, with 6 controls witho

39 received bevacizumab injections, 35 (44.9%) triamcinolone acetonide injections, and 5 (6.4%) a dexam

40 e suggested beneficial treatment effects for triamcinolone acetonide, interferon alpha-2a, and supple

41 Triamcinolone acetonide is toxic to proliferating cells

42 l retinal thickness (CRT) after intravitreal triamcinolone acetonide (IVT) injection for macular edem

43 Intravitreal triamcinolone acetonide (IVTA) is an effective treatment

44 usion (SCORE) Study showed that intravitreal triamcinolone acetonide (IVTA) is effective at reducing

45 In 3 eyes, intravitreal triamcinolone acetonide (IVTA) was injected within 8 wee

46 ne the human biodistribution and kinetics of triamcinolone acetonide, labeled with 11C, formulated an

47 n after posterior sub-Tenon's injection with triamcinolone acetonide levels in experimental undiluted

48 The theoretical model predicted that triamcinolone acetonide levels in systemic blood, vitreo

49 tocol, and swollen joints were injected with triamcinolone acetonide (maximum dosage 80 mg per month)

50 Intravitreal triamcinolone acetonide may be more effective than laser

51 CT-guided TMJ injections of corticosteroid (triamcinolone acetonide [n = 16] or triamcinolone hexace

52 ns were assessed 4 weeks after intramuscular triamcinolone acetonide: normalization of (1) symptoms (

53 rectomy and ILM peeling assisted with either triamcinolone acetonide or infracyanine green staining i

54 ular endothelial growth factor, intravitreal triamcinolone acetonide, or a combination of these thera

55 Intravitreal triamcinolone acetonide, pars plana vitrectomy, oral pro

56 ceived an average of 1.6 posterior sub-Tenon triamcinolone acetonide (PSTA) injections in the 12 mont

57 However, triamcinolone acetonide staining is associated with an i

58 Random assignment into 2 groups: 40-mg triamcinolone acetonide subacromial CSI versus 6 session

59 aoperative subconjunctival injection of 2 mg triamcinolone acetonide (TA) alone.

60 GR in complex with the potent glucocorticoid triamcinolone acetonide (TA) and a fragment of the small

61 culation on transscleral drug delivery using triamcinolone acetonide (TA) as a model drug.

62 racterize the safety and pharmacodynamics of triamcinolone acetonide (TA) delivered by this technique

63 ion of MR and GR activated by aldosterone or triamcinolone acetonide (TA) leads to significant transa

64 A novel conjugate of mitomycin C (MMC) and triamcinolone acetonide (TA) was synthesized using gluta

65 ating agents dexamethasone (Dex), IL-10, and triamcinolone acetonide (TA) were used to antagonize pro

66 Three agents-prednisolone acetate (PA), triamcinolone acetonide (TA), and lipid-based artificial

67 ty guidelines) and NONSA after intramuscular triamcinolone acetonide (TA), and to identify predictors

68 treated with 100 microM CoCl(2), 1 microg/mL triamcinolone acetonide (TA), or both.

69 oid receptor (GR) and c-jun transcription in triamcinolone acetonide (TA)-treated AtT-20 cells.

70 The inherent electron-capture properties of triamcinolone acetonide (TAA) fatty acid conjugates were

71 Triamcinolone acetonide (TAA) is an anti-inflammatory st

72 Intra-articular administered triamcinolone acetonide (TAA) is one of the drug treatme

73 , M: 770 microg, H: 1,540 microg per day and triamcinolone acetonide (TAA) L: 400 microg, M: 800 micr

74 properties of the C21 acetate derivative of triamcinolone acetonide (TAA) under methane chemical ion

75 ed this method to quantify the low levels of triamcinolone acetonide (TACA) in porcine plasma followi

76 Triamcinolone acetonide, the most commonly used intravit

77 bits received a subconjunctival injection of triamcinolone acetonide to one eye.

78 formulations encapsulating the model steroid triamcinolone acetonide (Tr-A) were implanted subcutaneo

79 uced cataract was observed in 4 intravitreal triamcinolone acetonide-treated patients (12%).

80 sion was documented in 22 (69%) intravitreal triamcinolone acetonide-treated vs 11 (34%) intravitreal

81 In summary, the use of inhaled triamcinolone acetonide was associated with loss of BMD

82 Carbon-11-labeled triamcinolone acetonide was formulated as the commercial

83 vehicle and with the vehicle alone, in which triamcinolone acetonide was suspended.

84 rong cytochrome P-450 3A (CYP3A) inducer] or triamcinolone acetonide (weak CYP3A inducer) produced do

85 ning to glaucoma in response to intravitreal triamcinolone acetonide will be reviewed.

86 the prospective Suprachoroidal Injection of Triamcinolone Acetonide with Intravitreal Aflibercept in

87 (>/=24 weeks) laser, or 4 mg of intravitreal triamcinolone acetonide with prompt laser.

88 duction when the R28 cells were treated with triamcinolone acetonide with vehicle (200 microg/mL) for

89 y of ARPE-19 and R28 cells after exposure to triamcinolone acetonide with vehicle 200 microg/mL for 2

90 Triamcinolone acetonide with vehicle caused a greater re

91 in the ARPE-19 cells when treated with both triamcinolone acetonide, with or without the vehicle at

92 he patient underwent periocular injection of triamcinolone acetonide, with resolution of the subretin

93 ial dehydrogenase activity when treated with triamcinolone acetonide without the vehicle at any of th